Safety of a specific COX-2 inhibitor in aspirin-induced asthma
about
sameAs
COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory diseaseSafety of COX-2 inhibitors in asthma patients with aspirin hypersensitivitySafety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxibAdverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospitalCOX-1 sparing drugs in aspirin-sensitive asthmaAspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest)A new insight into aspirin-induced asthmaThe role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitorsSafety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugsTesting for aspirin hypersensitivityThe safety of celecoxib in patients with aspirin-sensitive asthmaA comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthmaEffects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.Transcriptional regulation of COX-2: a key mechanism in the pathogenesis of nasal polyposis in aspirin-sensitive asthmatics?Nuclear factor-kappaB activity is down-regulated in nasal polyps from aspirin-sensitive asthmaticsAspirin intolerance in boy with primary ciliary dyskinesiaNonsteroidal anti-inflammatory drug-induced reactions and desensitizationTolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literatureEAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivityAngioedema associated with aspirin and rofecoxibEtoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugsManagement options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivityAspirin-exacerbated asthma.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs.Immediate-type allergy to drugs and related compounds: evaluation and management.Update on recent advances in the management of aspirin exacerbated respiratory disease.Aspirin Intolerance: Experimental Models for Bed-to-Bench.Role of aspirin and other nonsteroidal anti-inflammatory drugs in aspirin-exacerbated respiratory disease.Nonallergic drug hypersensitivity reactions.Pathogenesis of aspirin-exacerbated respiratory disease and reactions.NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity.Aspirin-exacerbated respiratory disease: characteristics and management strategies.Current complications and treatment of aspirin-exacerbated respiratory disease.COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.Bresol inhibits phosphodiesterase 4 gene expression and modulates the levels of select mediators of inflammation in human monocytic cells.Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema.[Aspirin-Intolerance-Syndrom : a common and interdisciplinary disease].NSAID-sensitive patients tolerate rofecoxib.Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance.
P2860
Q24796213-EE9DBF41-4144-4656-98B7-1D411CAA2F91Q28165516-E688FB5F-00E7-4E65-9041-F27018142A23Q28168018-BDB45905-C7FB-4432-8FD6-5AC953CD337AQ28177036-B0B861A4-9728-4EE0-8FC3-2F00CC584F9CQ28177176-9ABE8F0E-4F49-45CC-93E8-0DE587228E26Q28185884-A80AD34C-8AFC-466F-90F1-2B7BF441BC07Q28192535-4699482C-0200-4396-822B-A159426E31C7Q28192716-601F8CC4-2981-4866-A435-604DFDC354F5Q28192717-00525E93-0651-4544-9FDC-057AF3017E61Q28193348-6840585F-9B0F-4625-A4A9-5847B55C7B5BQ28193684-03A701AA-18CF-473A-B3AC-156515CA65BBQ28193908-5EE2E97B-24BA-4107-8B57-20E0AF49E754Q28194198-B1448554-80B4-4A59-A08B-4B6AA09AE9E1Q28195309-E962A1D7-5A00-432D-9B2A-7DBAC1939E9AQ28195310-581A1CDD-AE5F-4C74-B7E0-FC4D214181ACQ28195313-D225346E-C41F-438C-9F24-ECDF12CD0450Q28209835-F62BFC35-DB3F-4D34-B0A7-6D9F3091EF26Q28210177-66BF5256-7613-433B-872A-C639501B9DD0Q28211293-E2500ED6-485B-44DB-A2B2-BCF720000F86Q28212096-A0350E43-1FF0-460A-AD85-828223B76805Q28217821-DCAAF79B-D768-491F-8A14-0955F9442AC0Q28217965-2954E276-3259-4A8E-96A0-68450404DF67Q33846722-F053EAB4-E7AC-4F99-A451-556BA81AD3E9Q35195182-31231C18-C821-4AAB-809E-7E84821E29CDQ35827826-77FA0FFD-6013-4208-AEA2-780265E44F28Q36406780-65832D90-8CC6-4295-8975-41CA7C5785F7Q37485583-8C514DA9-BF7D-4EC3-8E4E-BA91DD59E508Q37692720-A38AA956-98B9-44C2-BE88-F800B0C57D4DQ37754746-5FCB0F1B-E51B-4850-A66A-C5E39FDFC1BBQ38029476-52635663-3BCA-4785-9E5D-CD9240357463Q38103710-FE4CBA04-7CE6-40E1-8DB9-DE2078EFF082Q38412095-B5BA9EBF-BFCF-4B1E-909E-C01200049397Q38455960-A2098F3B-DF53-4627-B497-BBCDB2D3FF68Q39000200-1B26A38B-4BB3-4504-AB90-9A08E03187A1Q41774677-E43DABC4-DBAC-4342-98B5-AE141094052AQ42727457-AFB4C6EE-7957-4B68-A1C8-037A89F2BD10Q42840344-3CD1442B-7DD0-46A4-927C-74DC1ED97F79Q42931539-EB10A6CF-E948-4B66-B532-282BAFD2DC83Q44237232-7B9D1C1F-5ED7-4962-AF5D-A5C9039E2354Q44596945-A1AD1CCE-3DBD-4D8D-89D8-8B6355C7F9BA
P2860
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@ast
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@en
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@nl
type
label
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@ast
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@en
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@nl
prefLabel
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@ast
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@en
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@nl
P2093
P2860
P1476
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
@en
P2093
E Nizankowska
G Bochenek
M Swierczynska
P2860
P304
P356
10.1046/J.1365-2222.2001.01075.X
P407
P577
2001-02-01T00:00:00Z